ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
CORM-2 protects against sepsis-associated encephalopathy by activating the Nrf2/SLC7A11/GPX4 axis to inhibit ferroptosis and neuroinflammation.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis-associated encephalopathy (SAE) is a serious neurological complication of sepsis for which targeted pharmacological therapy remains limited. Carbon monoxide-releasing molecule-2 (CORM-2) has anti-inflammatory and antioxidant properties, but its effects on ferroptosis in SAE are incompletely understood. We investigated the protective effects and underlying mechanisms of CORM-2 in complementary in vitro and in vivo SAE models. In LPS-treated HT22 hippocampal neuronal cells, CORM-2 (50 μM) improved cell viability, reduced lipid reactive oxygen species and malondialdehyde, preserved mitochondrial membrane potential, restored glutathione and superoxide dismutase, reduced ferrous iron accumulation, and suppressed pro-inflammatory cytokines. CORM-2 also promoted nuclear accumulation of nuclear factor erythroid 2-related factor 2 (Nrf2) and increased solute carrier family 7 member 11 (SLC7A11) and glutathione peroxidase 4 (GPX4), whereas Nrf2 knockdown markedly attenuated these effects. In an LPS-induced murine SAE model, intravenous CORM-2 (8 mg/kg) increased survival from 40 to 70%, improved neurological scores, reduced brain water content, and preserved hippocampal morphology. CORM-2 also reduced microglial activation and cerebral IL-1β, IL-6, and TNF-α. Pharmacological Nrf2 inhibition with ML385 diminished the protective effects of CORM-2, whereas the Nrf2 agonist oltipraz enhanced them. Inactive CORM-2 (iCORM-2) and DMSO vehicle did not reproduce the protective profile of active CORM-2. Collectively, these findings support a model in which CORM-2 protects against experimental SAE in association with activation of the Nrf2/SLC7A11/GPX4 axis, suppression of ferroptotic injury, and attenuation of neuroinflammation.
Indexed as
Identifiers
42711393What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.